Physician profile
Heavin B Maier
NPI 1861478869
$1,386.26
in general payments reported to CMS, 2019-2025
13 companies · $83.30 in 2025
The $83.30 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $19.40 · 2021: $43.51 · 2022: $15.45 · 2023: $373 · 2024: $435 · 2025: $83.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $614.63 | 2019-2024 | Rocklatan, Rhopressa, Simbrinza |
| Coopervision INC. | $138.93 | 2023-2024 | Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $132.26 | 2019 | |
| Bausch & Lomb Americas INC. | $130.16 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $118.98 | 2019-2023 | Lipiflow System Activator (Disposable) |
| Lkc Technologies, INC. | $48.64 | 2024 | |
| Shire North American Group INC | $47.58 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $43.25 | 2024-2025 | Xdemvy |
| Abbvie INC. | $34.05 | 2025 | |
| Sun Pharmaceutical Industries INC. | $22.40 | 2019 | |
| Maculogix, INC. | $20.53 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heavin Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.